Understand the source comparison
Dihexa vs P21: Research Protocol Comparison
Primary Mechanism HGF/c-Met activation → BDNF upregulation → synaptogenesis CNTF mimetic → JAK/STAT signaling → neuroprotection Dihexa builds synapses, P21 protects neurons. Mechanistically non-overlapping Optimal Research Context Learning enhancement, memory
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Primary Mechanism
- HGF/c-Met activation → BDNF upregulation → synaptogenesis
- CNTF mimetic → JAK/STAT signaling → neuroprotection
- Dihexa builds synapses, P21 protects neurons. Mechanistically non-overlapping
- Optimal Research Context
- Learning enhancement, memory consolidation, synapse loss models
- TBI recovery, stroke, neuroinflammation, metabolic stress
- Use Dihexa for plasticity, P21 for resilience
- Typical Dosing Range (Literature)
- 0.5–5 mg/kg in rodent models; human equivalent ~0.04–0.4 mg/kg
- 1–10 mg/kg in rodent models; human equivalent ~0.08–0.8 mg/kg
- Dihexa shows potency at lower doses; P21 requires higher dosing for effect
- Onset of Measurable Effects
- Synaptic density changes detectable within 7–14 days
- Neuroprotective markers appear within 24–72 hours post-injury
- Dihexa is slower-acting structural change; P21 is acute intervention
- Blood-Brain Barrier Penetration
- High (small molecule, ~600 Da)
- Moderate (tetrapeptide, ~400 Da, requires specific transport)
- Dihexa crosses BBB more readily; P21 penetration is dose-dependent
- Evidence Base
- Preclinical rodent models; no published human trials as of 2026
- Preclinical + limited clinical data via Cerebrolysin studies
- Both lack robust human trial data as standalone agents